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Cardiogenic programming of human pluripotent
stem cells by dose-controlled activation of EOMES
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Master cell fate determinants are thought to induce speciﬁc cell lineages in gastrulation by
orchestrating entire gene programs. The T-box transcription factor EOMES (eomesodermin)
is crucially required for the development of the heart—yet it is equally important for endo-
derm speciﬁcation suggesting that it may act in a context-dependent manner. Here, we deﬁne
an unrecognized interplay between EOMES and the WNT signaling pathway in controlling
cardiac induction by using loss and gain-of-function approaches in human embryonic stem
cells. Dose-dependent EOMES induction alone can fully replace a cocktail of signaling
molecules otherwise essential for the speciﬁcation of cardiogenic mesoderm. Highly efﬁcient
cardiomyocyte programming by EOMES mechanistically involves autocrine activation of
canonical WNT signaling via the WNT3 ligand, which necessitates a shutdown of this axis at
a subsequent stage. Our ﬁndings provide insights into human germ layer induction and bear
biotechnological potential for the robust production of cardiomyocytes from engineered stem
cells.
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Essentially all heart cells are descendants of Eomes-expressingcells in mouse development1–4. Similarly, most cells formingthe heart are derived from mesoderm precursors expressing
the bHLH transcription factor Mesp15,6. MESP1 has been pro-
posed to play a master regulatory role in cardiovascular speciﬁ-
cation7. This view is based on procardiac effects observed in
elegant MESP1 gain-of-function studies using mouse embryonic
stem (ES) cells and vertebrate embryos7–10.Mesp1 is a target gene
of EOMES and hence it is thought that EOMES exerts its car-
diogenic function through this mechanism1,11. However, neither
EOMES nor MESP1-expressing cells in the embryo exclusively
give rise to the cardiac lineage, since both genes also play pro-
minent roles in other contexts2,10,12,13. Accordingly, over-
expression studies in mouse ES cells have thus far yielded rather
moderate cardiogenic effects over background7–11. Therefore, the
issue of whether there is a bona ﬁde master regulatory factor
speciﬁcally promoting the induction of cardiac cells at high efﬁ-
ciency, and under which conditions it would do so, appears to be
unresolved.
Human ES cells (hESCs) present an excellent model system to
investigate such questions. This is because controlled differ-
entiation procedures, including directed cardiac induction pro-
tocols, are in part highly developed by now and these are based on
developmental principles14,15. In addition, genetic manipulation
tools have emerged that now permit systematic loss and gain-of-
function studies, in combination with modifying the extrinsic
signaling environment at high temporal resolution. Here, we
demonstrate that within an intermediate corridor of transcrip-
tional activation, EOMES may speciﬁcally activate a cardiogenic
program in hESCs. This alternative approach of promoting car-
diac induction does not require exogenous signaling cascade
activation, yet it necessitates an inhibition of the WNT pathway at
the cardiac mesoderm stage. Mechanistic investigation establishes
that this accessory requirement is based on a functional link
between EOMES and the WNT3 locus.
Results
EOMES knockout (KO) hESCs do not form cardiomyocytes
(CMs). Following up on our previous investigation of cardiac
induction mechanisms in the hESC system16, we subjected
EOMES KO hESCs to a stringent cardiac differentiation proto-
col17. At the cardiac mesoderm stage of this procedure18, day 2,
EOMES was conﬁrmed to be highly expressed in wild-type (WT)
cells and absent in KO ones (Fig. 1a). At day 8, WT cells had
formed beating monolayers expressing the early cardiomyocyte
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Fig. 1 EOMES knockout hESCs fail to differentiate into cardiomyocytes. a Immunoblot conﬁrming EOMES expression and its absence in WT and KO cells,
respectively, at the cardiac mesoderm stage of directed differentiation. b EOMES KO cells fail to express the early cardiomyocyte marker NKX2.5 following
exposure to a directed differentiation protocol. Scale bar: 50 µm. c EOMES KO cells show a general failure in markedly upregulating essential pan-cardiac
genes (qPCR data, n= 3; error bars: s.e.m.). For each gene, the expression level in the highest expressing sample (“max”=WT in all three cases) is set to 1.
d Differentiation of EOMES KO hESCs under signaling factor-assisted, non-cardiac mesoderm/endoderm-permissive culture conditions. Top: EOMES KO
cells fail to express α-fetoprotein following Activin A-assisted endodermal induction. Scale bar: 50 µm. Bottom: Non-cardiac mesodermal differentiation
competence of EOMES KO hESCs. KO cells were differentiated using varied meso and endoderm-permissive induction conditions. The data denote
transformed p-values of annotation terms enriched in gene sets upregulated in EOMES KO samples compared to undifferentiated hESCs or differentiated
WT controls (cutoffs: 10 or 3-fold, respectively). Underlying data: Supplementary Data 1
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marker NKX2.5 and other pan-cardiac genes, whereas EOMES
KO cells did virtually not express any of these (Fig. 1b, c).
Likewise, using Activin A-assisted differentiation conditions, WT
hESCs readily formed endodermal cells, whereas EOMES KO
cells entirely failed to do so, as expected from literature (Fig. 1d,
top).
Next, we asked whether EOMES deﬁciency would disable
somatic differentiation in general or, at least, globally prevent
mesodermal commitment. To this end, WT and EOMES KO
hESCs were subjected to spontaneous differentiation conditions
or to signaling factor-assisted, non-cardiac mesoderm-permissive
ones, as based on a previously established mesendodermal
patterning model16. EOMES KO cells readily differentiated along
the neural lineage (Supplementary Fig. 1a). Moreover, an
unbiased expression analysis of meso-permissive differentiation
cultures suggested that EOMES disruption preserves differentia-
tion competence into renal, mesenchymal, and endothelial
lineages (Fig. 1d, bottom, and Supplementary Data 1). Immuno-
ﬂuorescent stainings conﬁrmed the ability of EOMES KO cells to
differentiate into these exemplary cell types (Supplementary
Fig. 1b). Thus, with regard to mesodermal commitment, EOMES
is crucially required for CM formation but not for mesodermal
differentiation in general.
EOMES drives cardiac programming of hESCs at high efﬁ-
ciency. Given the severe failure of EOMES KO hESCs to form
CMs under directed differentiation conditions, we next asked
whether enforced EOMES induction could in turn drive the
process on its own. Using an inducible overexpression cell line on
EOMESKO background in which an EOMES transgene may be
activated using doxycycline (DOX) administration (EOMESKO/E.
TET-ON, Supplementary Fig. 2a)16, we modiﬁed the standard
cardiac induction procedure such that all cardiac mesoderm-
inducing signaling factors were replaced by DOX (Fig. 2a).
Optimization of the timing of DOX supplementation and that of
a WNT inhibitor added in a subsequent stage suggested that
3 days of DOX treatment combined with 2 days of WNT inhi-
bition (from 48–96 h) was most optimal (Supplementary Fig. 2b).
Strikingly, this protocol—devoid of any signaling pathway-
activating molecules—generated near-homogeneous monolayers
of beating CMs, similar to the standard procedure (Fig. 2b and
Supplementary Movie 1).
The hESC-CMs programmed by EOMES were termed pCMs
and characterized as follows. pCMs expressed structural markers
and ion channel genes involved in forming cardiac action
potentials, at similar levels compared to standard hESC-CMs
(Supplementary Fig. 2c). Furthermore, pCMs displayed robust
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Fig. 2 EOMES programs hESCs into functional CMs at high efﬁciency. a Illustration of growth factor-mediated and optimized EOMES induction-based
cardiac differentiation protocols. Bottom right: Immunoblot validating doxycycline-dependent EOMES expression in a transgenic EOMESKO/E.TET-ON hESC
line. b Typical yields of hESC-CMs (left, ﬂow cytometry) and NKX2.5 expression (right, immunoblot) obtained with the two protocols (day 10). c
Immunostainings 21 days after the initiation of EOMES induction. Weak perinuclear ANP staining is typical in overall MLC2v-positive hESC-CMs. Scale bars:
25 (top) and 50 µm (bottom). d Acceleration and slowdown of spontaneous beat rates in pCMs following exposure to 10 µM isoprenaline and 10 µM
propranolol, respectively, on multielectrode arrays. eMicroarray-based time course analysis comparing the indicated protocols and cell lines. RESCUE cells
carry an inducible EOMES transgene on EOMESKO HuES6 background. Underlying data are from Supplementary Data 2
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staining for cardiac markers at the protein level and showed a
striated sarcomeric pattern in many cells already by 3 weeks (wk)
(Fig. 2b, c). hESC-CMs tend to acquire an overall ventricular
subtype identity by default, whereas an atrial fate may be induced
by retinoic acid addition during early stages of differentiation19.
We adopted and employed this paradigm to assess the subtype
identity of pCMs. pCMs robustly expressed ventricular-speciﬁc
myosin light chain 2 in almost all cells and were essentially
deﬁcient in atrial-speciﬁc ANP expression (Fig. 2c). These and
other heart chamber-speciﬁc markers suggest that pCMs take on
an overall ventricular identity, similar to standard hESC-CMs but
different from retinoic acid-treated ones (Supplementary Fig. 2c).
To substantiate this conclusion, and to demonstrate the overall
physiological functionality of pCMs, these cells were treated with
E-4031, an inhibitor of the hERG potassium channel that plays a
key role in CM repolarisation20. E-4031 prolonged electrical ﬁeld
potential durations on multielectrode arrays indicating that hERG
is operative in pCMs (Supplementary Fig. 2d). Moreover, pCMs
did not display signiﬁcant ﬁeld potential prolongations upon
addition of 4-aminopyridine, an inhibitor of the atrial-speciﬁc
KCNA5 channel—much in contrast to standard atrial-like CMs
generated via transient retinoic acid treatment21 (Supplementary
Fig. 2e). Furthermore, pCMs showed physiological responses to
chronotropic drugs, namely, beat rate acceleration in response to
isoprenaline, an adrenergic agonist, and slowdown after addition
of propranolol which is a beta blocker (Fig. 2d). These data
indicate that pCMs compare well with conventional ventricular-
like hESC-CMs regarding their overall characteristics and
maturation features acquired upon prolonged in vitro culture17.
Differentiation fate is EOMES dose dependent. We next sought
to better understand cardiac programming by EOMES. A time
course gene expression analysis indicated that EOMES KO cells
not only failed to eventually upregulate a cardiac program but that
they were already lacking entire sets of mesodermal and primitive
streak genes at early differentiation stages. However, EOMES
induction via the TET-ON protocol fully restored the normal
sequence of events (Fig. 2e and Supplementary Data 2). Hence, the
similarity between conventional hESC-CMs and pCMs at later
stages is matched by highly similar induction kinetics of meso-
dermal and cardiac gene expression in the short term.
To check whether endogenous EOMES inﬂuences the efﬁcacy
of the transgenic induction system in a negative way, and to
further elucidate the requirements for pCM formation, we
additionally generated an EOMES TET-ON line on WT hESC
background (WTE.TET-ON hESCs, Supplementary Fig. 3a, b).
There was no apparent difference in cardiac differentiation
efﬁciencies, and in general the system conveniently allowed pCM
induction from routine hESC maintenance plates—simply by
adding DOX to subconﬂuent 6-well cultures (Supplementary
Movie 2). pCM induction efﬁciency, however, was highly
dependent on the DOX concentration used (Fig. 3a). Moreover,
the TET-ON protocol strictly required the inactivation of WNT
signaling in a subsequent differentiation stage (Fig. 3b). Outside
the pCM-compatible DOX range, the TET-ON protcol interest-
ingly gave rise to alternative mesendodermal differentation fates.
Hence, following low-DOX induction (0.125 µg/ml), these
included hepatic as well as putative hematopoetic cells character-
ized by hemoglobin gene expression. And following high-DOX
induction (1 µg/ml), WTE.TET-ON hESCs heterogeneously differ-
entiated into smooth muscle and mesenchymal fates (Supple-
mentary Fig. 3c, d). A similar dependence of cardiac induction on
the DOX concentration was also noticed in a third cell line
generated on an independent induced pluripotent stem cell
background21 (WTE.TET-ON hiPSCs, Supplementary Fig. 3e, f):
Only at a DOX concentration range of 0.1–0.13 µg/ml did this cell
line reproducibly form pCMs at high efﬁciency (Fig. 3c and
Supplementary Movie 3).
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Cardiogenic activity of EOMES is crucially linked to WNT3.
This behavior was reminiscent of our standard growth factor-
based protocol in which the BMP and/or WNT signaling
pathways can easily be under or overstimulated, giving rise to
non-cardiac fates in such cases16. We hence hypothesized that
the profound impact of EOMES on global gene expression
programs may in part be based on a link to WNT or BMP
signaling. Short-term WNT and BMP stimulation experiments
deﬁned pathway-speciﬁc target genes in hESCs (Supplementary
Data 3). Some of the most stringent ones were then monitored
in the TET-ON differentiation time course. This analysis indi-
cated that during the ﬁrst 2 days of EOMES induction, target
genes of canonical WNT signaling became strongly upregulated,
whereas BMP-linked genes only showed a response thereafter
(Fig. 4a). Notably, some of the early-induced WNT targets, like
MSX1 and CDX1/2, are known to be counterproductive for
cardiac differentiation16. Their upregulation explains the
necessity for subsequent WNT inhibition and argues for the
involvement of a global—not necessarily cardiac-speciﬁc—
WNT response. As expected, WNT inhibition during the ﬁrst
2 days of DOX treatment prevented the upregulation of WNT
targets including T (Brachyury), indicating that EOMES alone
was not sufﬁcient for their induction (Supplementary Fig. 4a).
Similar treatments also suppressed cardiac differentiation in the
longer term, which demonstrates the functional importance of
an initial activation of WNT signaling downstream of EOMES
(Fig. 4b, top). In comparison, early BMP inhibition only had a
mild effect (Fig. 4b, bottom).
To identify a possible mechanism for these observations, the
TET-ON differentiation time course data set was mined for the
early induction of genes encoding canonical WNT signaling
ligands (Supplementary Data 2). Two such genes, WNT3 and
WNT3A, were markedly upregulated by EOMES overexpression
within 1–2 days (Fig. 4c). Both of these were also bound by
EOMES in differentiating hESCs, according to a previously
published ChIP-seq data set13. Using ChIP-qPCR amplicons
overlapping with the corresponding promoter regions, we were
able to conﬁrm WNT3—but not WNT3A—as a direct EOMES
target gene in our protocol (Fig. 4d). Nonetheless, we sought to
investigate the functional implication of both ligand-encoding
genes in an unbiased manner. Hence, we prepared homozygous
KO hESC lines for both WNT3 and WNT3A using quadruple
CRISPR/Cas9n DNA nicking22. To account for a potential
compensation between the two targeted genes, we also generated
a WNT3/WNT3A double knockout line (DKO, see Methods and
Supplementary Table 1). These lines were prepared on WTE.TET-
ON background to later be able to challenge WNT ligand function
using the TET-ON protocol. The induced splice mutations caused
the predicted exon 2 deletions and associated reading frame shifts
at the RNA level, as evidenced by exon-spanning RT-PCR and
cDNA sequencing (Fig. 4e and Supplementary Fig. 4b).
DOX supplementation for 2 days induced SP5, a stringent
WNT-speciﬁc target gene in hESCs, only in WTE.TET-ON cells as
well as in the WNT3A KO line, but not in WNT3 KO or WNT3/
WNT3A DKO cells (Supplementary Fig. 4c). These data indicate
that WNT3, not WNT3A, mediates the EOMES-induced WNT
response early in the protocol. Furthermore, they predicted that
CM formation would be compromised in the WNT3 mutant
lines. Indeed, cardiac differentiation efﬁciencies were unaffected
in WNT3A KO cells but severely diminished in WNT3 KO and
WNT3/WNT3A DKO ones (Fig. 4f, g, top panel). Finally, to
formally demonstrate that this phenotype in WNT3-deﬁcient
cells was due to the speciﬁc disruption of the gene rather than due
to unspeciﬁc effects, we used exogenous WNT activation to
compensate for it. Indeed, an additional treatment with
CHIR99021, a GSK3 inhibitor, rescued the genetic defect to
restore cardiac differentiation competence in the two WNT3-
deﬁcient lines (Fig. 4g, bottom).
Discussion
Overall, these data suggest that the fundamental role of EOMES
in germ layer induction2,12 goes beyond activating individual
factors downstream in the differentiation cascade, although the
stimulation of genes like Mesp1 is certainly very important,
too1,11. Rather, we propose that much of the function of EOMES
is intimately based on a cooperative interplay with the WNT
pathway, at least in cardiac mesoderm speciﬁcation. Both EOMES
and WNT are crucially required for cardiac induction. Under
cardiac-permissive conditions, WNT signaling activates
EOMES16. Conversely, EOMES promotes WNT signaling
through the induction of WNT3 as shown here. The two entities
hence form a self-sustaining regulatory module in cardiac
mesoderm speciﬁcation (Fig. 4h). In this model, cardiac induction
may either be accomplished through exogenous WNT activation
as in WNT-driven cardiac differentiation protocols23,24, or by
intrinsic EOMES induction as shown here—the module becomes
activated in both ways. These mutual links between EOMES and
WNT3 are likely to have in vivo relevance as Wnt3 is funda-
mentally required for mouse primitive streak formation, whereas
Wnt3a only plays a role at later stages25,26.
Overampliﬁcation of the module promotes non-cardiac fates.
To prevent this from happening in vivo, migratory cardiac
mesoderm cells assume residence at the anterior side of the
embryo where they become exposed to WNT-antagonizing fac-
tors, which will inactivate the regulatory circuit and counteract
anti-cardiac gene expression16,27. In a cell culture setting, WNT
or EOMES need to be dose-controlled to prevent the module
from overshooting and additionally, sustained signaling is to be
inhibited in a subsequent step (Fig. 4h). In this regard, EOMES
may be considered a context-dependent master regulator of
cardiac speciﬁcation. The fact that this key inductive function is
highly dose and context-dependent may explain why it remained
somewhat underestimated in a previous report using mouse ES
cells11. Overall, the signaling context appears to have a profound
impact on differentiation driven by intrinsic cell fate determi-
nants. For instance, activation of Nodal-SMAD2/3 signaling
cooperates with EOMES to redirect cell fate along the endodermal
lineage11,13. And even classical examples such as MYOD1-driven
forward programming of hESCs into skeletal muscle requires
concomitant retinoic acid signaling for optimal outcomes28.
Hence, environmental constraints do not question but may
overshadow key roles of intrinsic regulators in cell fate
programming.
From a practical point of view, EOMES-driven cardiac
induction may, even though the approach relies on genetic
modiﬁcation, bear advantages for the robust production of CMs
at a larger scale. pCMs display functional properties comparable
to conventional hPSC-CMs but their generation could con-
veniently be initiated from routine cultures and appeared to be
easier to control than growth factor-based differentiation in our
hands. These observations hence encourage a more detailed
analysis of pCM physiology to serve in drug testing and disease
modeling paradigms. Furthermore, it will be interesting to
investigate whether there are additional master determinants of
human cardiac induction acting at more downstream stages of
the differentiation process.
Methods
hESC culture. WT hESCs (HuES629 background, obtained from Harvard Uni-
versity), WT hiPSCs (F1 background, fetal liver ﬁbroblast-derived21), and their
genetically modiﬁed derivatives were maintained on 6-well dishes coated with 1 ml/
well 1:75 diluted Matrigel™ HC (Corning #354263), in deﬁned FTDA medium30.
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FTDA was composed of DMEM/F12, 1 × PenStrep/Glutamine, 1 × deﬁned lipids
(Thermo), 1 × ITS (Corning), 0.1% human serum albumin (Biological Industries),
10 ng/ml FGF2 (PeproTech #100-18B), 0.2 ng/ml TGFβ1 (eBioscience #34-8348-
82), 50 nM Dorsomorphin (Santa Cruz), and 5 ng/ml Activin A (eBioscience #34-
8993-85). Fully conﬂuent hPSC cultures were harvested by a 15–20 min incubation
with Accutase™ (Sigma) containing 10 µM ROCK inhibitor Y-27632 (abcamBio-
chemicals) and seeded out for passaging into new 6-well plates at 400,000–500,000
cells per well, in FTDA + ROCKi. Cells were split every 3–4 days and kept in
culture for a maximum of 30 passages. Short-term signaling stimulation experi-
ments were carried out using semiconﬂuent cultures.
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Genetic manipulation. For the induction of splice mutations, two pairs of
CRISPR/Cas9 nickase vectors were designed to encompass intron–exon bound-
aries. CRISPR vectors were generated by oligonucleotide cloning as described16,
using the pX335 vector31 (Addgene plasmid #42335) modiﬁed to contain a GFP-
2A-puromycin selection cassette. gRNA-speciﬁc targeting sequences are given in
Supplementary Table 2. For disrupting a given locus, hESCs were transfected with
the four corresponding CRISPR vectors using Fugene™ HD (Promega). For
simultaneously disrupting two genes, hESCs were accordingly transfected with a
cocktail of eight plasmids. One day later, transfectants were enriched using tran-
sient puromycin selection for 1 d (0.5 µg/ml). Two days later, semiconﬂuent cul-
tures were replated at clonal density. Half the cells from single emerging colonies
were used for DNA isolation and gPCR screening using deletion-spanning primers
given in Supplementary Table 2. PCR-positive candidate clones vs. total number of
clones screened: 3/24 (WNT3), 4/32 (WNT3A), 1/24 (WNT3/WNT3A DKO). The
remaining half-colonies from positive clones were expanded and (re-)validated by
diagnostic PCRs on gDNA and cDNA templates, as well as by sequencing of
multiple TOPO/TA clones. One cell clone per genotype was used in experiments.
Clonal DOX-inducible overexpression lines were generated using PiggyBac
transposition as described16. Three vectors containing PiggyBac-ﬂanked inducible
EOMES-HA-IRES-Venus, PiggyBac-ﬂanked constitutive rTA-IRES-NEO, and
constitutive transposase transgenes were co-transfected into hPSCs using Fugene
HD, at a DNA mass ratio of 10:1:3, respectively. Stable transgene-positive cells were
selected using 50 µg/ml G418 and replated at low density. Emerging colonies were
split in half and replated. One plate was test-induced for 1 day using DOX, and if
homogeneous green ﬂuorescence was observed for a given clone the uninduced
replicate culture was picked, expanded, and characterized as appropriate.
Differentiation. Standard growth factor-mediated cardiac induction was per-
formed under serum and albumin-free conditions as described17. Brieﬂy, fully
conﬂuent hESC cultures were harvested using Accutase resuspended in day 0
differentiation medium and seeded out at 500,000 cells/well in Matrigel-coated 24-
well plates (2 ml volume/well). Day 0 differentiation medium consisted of KO-
DMEM, 1 × ITS, 10 µM Y-27632, 1 × PenStrep/Glutamine, 10–20 ng/ml FGF2, 0 or
5 ng/ml Activin A, 0.5–1 ng/ml BMP4 (R&D #314-BP-050), and 1 µM CHIR99021
(AxonMedchem #Axon 1386). From day 1 onward, the basal differentiation
medium consisted of KO-DMEM, 1 × TS (transferrin/selenium), 250 µM 2-phos-
pho-ascorbate, and PenStrep/Glutamine. WNT inhibitor C-59 (Tocris #5148) was
added to the cultures from 48 to 96 h of differentiation at 0.2 µM. Optionally, for
promoting an atrial fate, all-trans-retinoic acid (Sigma #R2625) was supplemented
from 72 to 120 h of differentiation. Differentiation medium was changed on a daily
basis.
For investigating non-cardiac differentiation fates, the above culture conditions
were modiﬁed according to a previously established mesendodermal patterning
model16, by varying the initial BMP4 dose administered, or by additional Activin A
supplementation, and/or by omitting the addition of the WNT inhibitor in the
second differentiation step. Neural differentiation was promoted by standard
embryoid body-based procedures.
For EOMES-driven cardiac differentiation, transgenic hESCs were either
replated into Matrigel-coated 24-well plates in FTDA + ROCKi (1 M cells/well), to
initiate differentiation the day after or, alternatively, differentiated directly from
subconﬂuent (day 3) maintenance cultures in 12 or 6-well format. Basal
differentiation medium was identical to that in the growth factor-based protocol.
Insulin addition on day 0 was optional. DOX was administered for the ﬁrst 3 days
at 0.25 µg/ml in case of the two HuES6 derivative cell lines, or at 0.1–0.13 µg/ml in
case of the WTE.TET-ON hiPSC line. C-59 was applied from day 2 to 3 at 0.2 µM
unless stated otherwise. For investigating non-cardiac differentiation with the TET-
ON protocol using WTE.TET-ON hESCs, the DOX concentration used was lowered
(0.125 µg/ml) or increased (1 µg/ml). Cultures differentiated this way were analyzed
by means of microarrays followed by validation of selected markers at the protein
level.
For CM maturation, beating monolayers emerging at day 6–8 were dissociated
using TrypLE Select (Thermo) on day 8–10 and replated at a ratio of ~1:4 using
CM splitting medium which consisted of RPMI 1640 (Thermo), 1 × ITS, 0.1%
HSA, 250 µM phospho-ascorbate, 0.008% thioglycerol, 1 × PenStrep/Glutamine,
and 10 µM ROCKi. Next day, medium was replaced by CM maintenance medium
consisting of KO-DMEM, 1 × ITS, 0.1% (w/v) HSA, 1 × deﬁned lipids, 250 µM
phospho-ascorbate, 0.008% thioglycerol, and PenStrep/Glutamine. 1.5–2 wk later,
cultured CMs were used for downstream analyses as indicated.
RT-qPCR. RNA was isolated using NucleoSpin RNA kits with on-column DNase
treatment (Machery Nagel). Reverse transcription was performed using M-MLV
reverse transcriptase (Affymetrix #78306) with oligo-dT15 priming at 42 °C. Real-
time PCR was carried out using validated primers given in Supplementary Table 2
and BioRad iTaq™ Universal SYBR Green Supermix on ABI instrumentation. The
ΔΔCt method was used to calculate relative transcript abundance against a ﬁxed
reference sample or against the highest expressing sample of a given series.
Alternatively, results were expressed relative to a housekeeeping gene standard
(RPL37A, 2−ΔCt). Statistics were based on RPL37A-corrected Ct values or fold
expression changes, as appropriate. Conventional RT-PCRs were performed
according to standard procedures.
Genome-wide expression analysis. Labeled cRNA was prepared from 500 ng
DNA-free RNA samples using TotalPrep™ linear RNA ampliﬁcation kits (Thermo
#AMIL1791). Microarray hybridizations on Illumina V4 human HT-12 bead arrays
were carried out as recommended by the manufacturer. Cy3-stained chips were
scanned using HiScan SQ instrumentation. Background subtraction and cubic
spline normalization was done using GenomeStudio software. Processed data were
ﬁltered in MS Excel by setting experience-based thresholds for expression changes
and minimal gene expression levels. For functional annotation of ﬁltered gene lists,
employing the Ensembl BioMart interface, array probe sequences were converted
into GRCh37/hg19 genome coordinates which were then used as input for GREAT
analysis32. Statistically signiﬁcant hits were subjectively ﬁltered for biological
relevance and presented based on the obtained p-values.
ChIP-qPCR. Chromatin immunoprecipitation was performed as described16, using
samples differentiated until the cardiac mesoderm stage (day 2). HA tag-based
ChIP (Santa Cruz #sc-805-X) was used due to the temporal unavailability of a
ChIP-grade EOMES antibody. IgG control was Santa Cruz #sc-2027. qPCRs were
performed using diluted ChIP and serial dilutions of input DNA. Fold enrichments
over input were calculated following internal normalization to an irrelevant control
locus. Primers are given in Supplementary Table 2.
Immunocytochemistry. Immunoﬂuorescence analysis was carried out according
to standard procedures using secondary Alexa-488 or Alexa-568-conjugated anti-
bodies and Hoechst for ﬂuorescent staining. Primary antibodies were α-actinin
(Sigma #A7811, 1:800), albumin (R&D #MAB1455, 1:100, albumin-free staining
procedure), ANP (R&D #AF3366, 1:100), α-fetoprotein (Sigma A8452, 1:500),
COL3A1 (Santa Cruz #sc-8780-R, 1:100), HA tag (Santa Cruz #sc-806-X, 1:200),
MLC2v (ProteinTech Group #10906-1-AP, 1:200), NKX2.5 (R&D #AF2444, 1:100),
PECAM1 (R&D #BBA7, 1:50), smooth muscle actin (DakoCytomation #M085129-
2, 1:100), SOX2 (R&D #AF2018, 1:200), cardiac troponin I (cTnI, Santa Cruz #sc-
15368, 1:200), cardiac troponin T (cTnT, Thermo #MS-295-P, 1:200), renin (R&D
#AF4090, 1:150), β-III-tubulin (Covance #MMS-435P, 1:500), and vimentin (Sigma
#V6630, 1:200).
Immunoblotting. Western blotting was performed according to standard proce-
dures using peroxidase-conjugated secondary antibodies and SuperSignal® West
Pico chemiluminescent substrate (Thermo). Primary antibodies were EOMES
(Abcam #ab23345, 1:1000), GAPDH (Thermo #AM4300, 1:10,000), and NKX2.5
(R&D #AF2444, 1:100). All uncropped immunoblots can be found in Supple-
mentary Fig. 5.
Flow cytometry. Flow cytometry was carried out following Accutase digestion of
primary monolayers or replated CMs, ﬁxation with 2% formaldehyde, and
blocking/antibody incubations in FACS buffer (0.5% saponin/5% fetal calf serum in
PBS). Antibodies used were cTnT (Thermo #MS-295-P, 1:200) and Alexa-488 anti-
mouse (Thermo #A11001, 1:1000).
Electrophysiological analysis. For analysis of pCMs on microelectrode arrays
(USB-MEA256 system, Multichannel Systems), the electrode areas of plasma-
cleaned 9-well MEAs were coated with 3 µl of a 1:75 diluted Matrigel solution in
KO-DMEM for approximately 2 h at 37 °C in a humidiﬁed cell culture incubator.
pCMs were dissociated from maintenance cultures using a 10 × TrypLE Select
digestion to obtain a single-cell/small aggregate suspension. Coating solution was
removed from the electrode arrays to be replaced by 25,000–50,000 cells resus-
pended in a ~3 µl droplet of CM splitting medium. CMs were allowed to attach for
~30 min. Subsequently, MEA chambers with attached cells were ﬁlled with 150 µl
of CM replating medium. Next day, medium was changed to CM maintenance
medium. From the following day onward, cell preparations were used for
recordings at 37 °C. Drugs were washed in for 5 min (isoprenaline: 10 µM, pro-
pranolol: 10 µM, E-4031: 100 nM, 4-AP: 1 mM). Algorithms for determining ﬁeld
potential durations as QTmax-like intervals were implemented in MC Rack software
v4.5.7. Extracted values were averaged from independent replicates. Beat frequency
correction was based on Bazett’s formula.
Statistics and reproducibility. Essentially every result was conﬁrmed in at least
one additional experiment. The TET-ON protocol has independently been
reproduced multiple times by three individuals, with highly similar outcomes.
Unless stated otherwise, numerical data represent means of n biological replicates,
as indicated in ﬁgure legends. Error bars of qPCR data denote s.e.m., and those of
microarray data reﬂect bead standard deviation. Where meaningful, 1 or 2-sided
unpaired t-tests were used, as appropriate, to compare pairs of samples in MS
Excel. Asterisk denotes a signiﬁcance level of p< 0.05, and **p< 0.01. Statistics on
microarray data were based on an Illumina custom model implemented in Gen-
omeStudio software.
Data availability. The authors declare that all data supporting the ﬁndings of this
study are available within the article and its Supplementary Information ﬁles or
from the corresponding author upon reasonable request. Raw and processed
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microarray data have been deposited in the Gene Expression Omnibus (NCBI
GEO) database under accession codes GSE97627 (cardiac induction time courses
related to Supplementary Data 2) and GSE97625 (short-term stimulation experi-
ment related to Supplementary Data 3).
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